<?release-delay 0|0 ?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties no_embargo?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Crystallogr Sect F Struct Biol Cryst Commun</journal-id><journal-id journal-id-type="publisher-id">Acta Cryst. F</journal-id><journal-title>Acta Crystallographica Section F: Structural Biology and Crystallization Communications</journal-title><issn pub-type="epub">1744-3091</issn><publisher><publisher-name>International Union of Crystallography</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">pu5123</article-id><article-id pub-id-type="doi">10.1107/S1744309106012036</article-id><article-id pub-id-type="coden">ACSFCL</article-id><article-id pub-id-type="pii">S1744309106012036</article-id><article-categories><subj-group subj-group-type="heading"><subject>Crystallization Communications</subject></subj-group></article-categories><title-group><article-title>Preliminary X-ray crystallographic analysis of the secreted chorismate mutase from <italic>Mycobacterium tuberculosis</italic>: a tricky crystallization problem solved</article-title><alt-title>Chorismate mutase</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Krengel</surname><given-names>Ute</given-names></name><xref ref-type="aff" rid="a">a</xref><xref ref-type="aff" rid="b">b</xref><xref ref-type="corresp" rid="cor">*</xref></contrib><contrib contrib-type="author"><name><surname>Dey</surname><given-names>Raja</given-names></name><xref ref-type="aff" rid="a">a</xref></contrib><contrib contrib-type="author"><name><surname>Sasso</surname><given-names>Severin</given-names></name><xref ref-type="aff" rid="c">c</xref></contrib><contrib contrib-type="author"><name><surname>&#x000d6;kvist</surname><given-names>Mats</given-names></name><xref ref-type="aff" rid="a">a</xref><xref ref-type="aff" rid="b">b</xref></contrib><contrib contrib-type="author"><name><surname>Ramakrishnan</surname><given-names>Chandra</given-names></name><xref ref-type="aff" rid="c">c</xref></contrib><contrib contrib-type="author"><name><surname>Kast</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="c">c</xref></contrib><aff id="a"><label>a</label>Department of Chemistry and Bioscience, Chalmers University of Technology, PO Box 462, SE-40530 G&#x000f6;teborg, <country>Sweden</country></aff><aff id="b"><label>b</label>Department of Chemistry, University of Oslo, PO Box 1033, Blindern, N-0315 Oslo, <country>Norway</country></aff><aff id="c"><label>c</label>Laboratory of Organic Chemistry, ETH Zurich, CH-8093 Zurich, <country>Switzerland</country></aff></contrib-group><author-notes><corresp id="cor">Correspondence e-mail: <email>ute.krengel@kjemi.uio.no</email></corresp></author-notes><pub-date pub-type="collection"><day>01</day><month>5</month><year>2006</year></pub-date><pub-date pub-type="epub"><day>12</day><month>4</month><year>2006</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>5</month><year>2006</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="collection"/>. --><volume>62</volume><issue>Pt 5</issue><issue-id pub-id-type="publisher-id">f060500</issue-id><fpage>441</fpage><lpage>445</lpage><history><date date-type="received"><day>05</day><month>12</month><year>2005</year></date><date date-type="accepted"><day>03</day><month>4</month><year>2006</year></date></history><permissions><copyright-statement>&#x000a9; International Union of Crystallography 2006</copyright-statement><copyright-year>2006</copyright-year><license license-type="open-access" xlink:href="http://journals.iucr.org/services/termsofuse.html"><p>This is an open-access article distributed under the terms described at http://journals.iucr.org/services/termsofuse.html.</p></license></permissions><self-uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1107/S1744309106012036">A full version of this article is available from Crystallography Journals Online.</self-uri><abstract abstract-type="toc"><p>A method is presented that allowed the diffraction limit of crystals of the secreted chorismate mutase from <italic>M. tuberculosis</italic> to be improved from approximately 3.5 to 1.3&#x02005;&#x000c5;. To obtain large well diffracting crystals, it was critical to initiate crystallization at higher precipitant concentration and then transfer the drops to lower precipitant concentrations within 5&#x02013;15&#x02005;min.</p></abstract><abstract><p>Chorismate mutase catalyzes the conversion of chorismate to prephenate in the biosynthesis of the aromatic amino acids tyrosine and phenylalanine in bacteria, fungi and plants. Here, the crystallization of the unusual secreted chorismate mutase from <italic>Mycobacterium tuberculosis</italic> (encoded by Rv1885c), a 37.2&#x02005;kDa dimeric protein belonging to the AroQ<sub>&#x003b3;</sub> subclass of mutases, is reported. Crystal optimization was non-trivial and is discussed in detail. To obtain crystals of sufficient quality, it was critical to initiate crystallization at higher precipitant concentration and then transfer the drops to lower precipitant concentrations within 5&#x02013;15&#x02005;min, in an adaptation of a previously described technique [Saridakis &#x00026; Chayen (2000<xref ref-type="bibr" rid="bb31"> &#x025b6;</xref>), <italic>Protein Sci.</italic><bold>9</bold>, 755&#x02013;757]. As a result of the optimization, diffraction improved from 3.5 to 1.3&#x02005;&#x000c5; resolution. The crystals belong to space group <italic>P</italic>2<sub>1</sub>, with unit-cell parameters <italic>a</italic> = 42.6, <italic>b</italic> = 72.6, <italic>c</italic> = 62.0&#x02005;&#x000c5;, &#x003b2; = 104.5&#x000b0;. The asymmetric unit contains one biological dimer, with 167 amino acids per protomer. A soak with a transition-state analogue is also described.</p></abstract><kwd-group><kwd>AroQ fold</kwd><kwd>ligand complex</kwd><kwd>nucleation</kwd><kwd>pathogenic bacterium</kwd><kwd>secreted chorismate mutase</kwd><kwd>shikimate pathway</kwd><kwd>transition-state analogue</kwd><kwd>equilibration kinetics</kwd><kwd>protein crystallization</kwd></kwd-group></article-meta></front><body><sec sec-type="introduction" id="sec1"><label>1.</label><title>Introduction</title><p>The biosynthesis of amino acids is an essential process in living cells as it provides the building blocks for polypeptides and important primary and secondary metabolites. The shikimate pathway is the anabolic pathway employed by bacteria, fungi and plants to synthesize the aromatic amino acids phenylalanine (Phe), tyrosine (Tyr) and tryptophan (Trp) (Haslam, 1993<xref ref-type="bibr" rid="bb13"> &#x025b6;</xref>). Chorismate mutase (CM; EC 5.4.99.5) is located at the branch point of the shikimate pathway and channels chorismate into the Tyr/Phe-specific branch. The enzyme catalyzes the conversion of chorismate to prephenate, which is formally a Claisen rearrangement. Chorismate mutases typically accelerate the uncatalyzed rearrangement by roughly one million-fold (Andrews <italic>et al.</italic>, 1973<xref ref-type="bibr" rid="bb2"> &#x025b6;</xref>). As one of the few enzymes known to catalyze a pericyclic process, it has generated considerable interest among enzymologists and bioorganic and computational chemists, specifically with respect to the origins of the catalytic efficiency (Andrews <italic>et al.</italic>, 1973<xref ref-type="bibr" rid="bb2"> &#x025b6;</xref>; G&#x000f6;risch, 1978<xref ref-type="bibr" rid="bb9"> &#x025b6;</xref>; Chook <italic>et al.</italic>, 1994<xref ref-type="bibr" rid="bb7"> &#x025b6;</xref>; Haynes <italic>et al.</italic>, 1994<xref ref-type="bibr" rid="bb14"> &#x025b6;</xref>; Wiest &#x00026; Houk, 1995<xref ref-type="bibr" rid="bb39"> &#x025b6;</xref>; Lee, Stewart <italic>et al.</italic>, 1995<xref ref-type="bibr" rid="bb21"> &#x025b6;</xref>; Kast, Asif-Ullah &#x00026; Hilvert, 1996<xref ref-type="bibr" rid="bb15"> &#x025b6;</xref>; Kast, Asif-Ullah, Jiang <italic>et al.</italic>, 1996<xref ref-type="bibr" rid="bb16"> &#x025b6;</xref>; Ma <italic>et al.</italic>, 1998<xref ref-type="bibr" rid="bb22"> &#x025b6;</xref>; Mattei <italic>et al.</italic>, 1999<xref ref-type="bibr" rid="bb25"> &#x025b6;</xref>; Gustin <italic>et al.</italic>, 1999<xref ref-type="bibr" rid="bb12"> &#x025b6;</xref>; Kast <italic>et al.</italic>, 2000<xref ref-type="bibr" rid="bb17"> &#x025b6;</xref>; Kienh&#x000f6;fer <italic>et al.</italic>, 2003<xref ref-type="bibr" rid="bb18"> &#x025b6;</xref>; Guo <italic>et al.</italic>, 2003<xref ref-type="bibr" rid="bb11"> &#x025b6;</xref>; Guimar&#x000e3;es <italic>et al.</italic>, 2003<xref ref-type="bibr" rid="bb10"> &#x025b6;</xref>; &#x00160;trajbl <italic>et al.</italic>, 2003<xref ref-type="bibr" rid="bb34"> &#x025b6;</xref>; Zhang <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb44"> &#x025b6;</xref>).</p><p>Structures have been determined for chorismate mutases from <italic>Bacillus subtilis</italic> (Chook <italic>et al.</italic>, 1993<xref ref-type="bibr" rid="bb8"> &#x025b6;</xref>, 1994<xref ref-type="bibr" rid="bb7"> &#x025b6;</xref>; Ladner <italic>et al.</italic>, 2000<xref ref-type="bibr" rid="bb19"> &#x025b6;</xref>), <italic>Escherichia coli</italic> (Lee, Karplus <italic>et al.</italic>, 1995<xref ref-type="bibr" rid="bb20"> &#x025b6;</xref>), <italic>Saccharomyces cerevisiae</italic> (Xue <italic>et al.</italic>, 1994<xref ref-type="bibr" rid="bb42"> &#x025b6;</xref>; Str&#x000e4;ter <italic>et al.</italic>, 1996<xref ref-type="bibr" rid="bb35"> &#x025b6;</xref>, 1997<xref ref-type="bibr" rid="bb36"> &#x025b6;</xref>) and the catalytic antibody 1F7 with chorismate mutase activity (Haynes <italic>et al.</italic>, 1994<xref ref-type="bibr" rid="bb14"> &#x025b6;</xref>). Recently, coordinates have also been deposited in the PDB for chorismate mutases from <italic>Thermus thermophilus</italic> (PDB codes <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore.do?structureId=1ode">1ode</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore.do?structureId=1ufy">1ufy</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore.do?structureId=1ui9">1ui9</ext-link>) and <italic>Clostridium thermocellum</italic> (PDB code <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore.do?structureId=1xho">1xho</ext-link>; Xu <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb41"> &#x025b6;</xref>). Interestingly, these examples comprise three completely unrelated folds: while the structurally characterized enzymes from <italic>B. subtilis</italic>, <italic>T.&#x000a0;thermophilus</italic> and <italic>C. thermocellum</italic> have a trimeric pseudo-&#x003b1;/&#x003b2;-barrel fold typical of the so-called AroH class of chorismate mutases (Chook <italic>et al.</italic>, 1994<xref ref-type="bibr" rid="bb7"> &#x025b6;</xref>; MacBeath <italic>et al.</italic>, 1998<xref ref-type="bibr" rid="bb23"> &#x025b6;</xref>), 1F7 exhibits the characteristic immunoglobulin &#x003b2;-sheet topology. The chorismate mutases of the AroQ class adopt yet another fold, which is dominated by &#x003b1;-helices. Its prototype, the chorismate mutase domain (AroQ<sub>p</sub>) of the bifunctional <italic>E. coli</italic> chorismate mutase-prephenate dehydratase (also known as EcCM), is an intertwined homodimer that comprises three &#x003b1;-helices per monomer (Lee, Karplus <italic>et al.</italic>, 1995<xref ref-type="bibr" rid="bb20"> &#x025b6;</xref>). This fold has recently been classified as AroQ<sub>&#x003b1;</sub> (&#x000d6;kvist <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="bb28"> &#x025b6;</xref>). The allosteric yeast chorismate mutase represents the AroQ<sub>&#x003b2;</sub> subclass (&#x000d6;kvist <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="bb28"> &#x025b6;</xref>), a more elaborate version of the basic AroQ fold, which shares weak sequence similarity with EcCM and possesses a structurally related active-site domain (Xue <italic>et al.</italic>, 1994<xref ref-type="bibr" rid="bb42"> &#x025b6;</xref>; Xue &#x00026; Lipscomb, 1995<xref ref-type="bibr" rid="bb43"> &#x025b6;</xref>; Str&#x000e4;ter <italic>et al.</italic>, 1996<xref ref-type="bibr" rid="bb35"> &#x025b6;</xref>, 1997<xref ref-type="bibr" rid="bb36"> &#x025b6;</xref>).</p><p>A third AroQ subclass, initially known as *AroQ (Xia <italic>et al.</italic>, 1993<xref ref-type="bibr" rid="bb40"> &#x025b6;</xref>; Calhoun <italic>et al.</italic>, 2001<xref ref-type="bibr" rid="bb5"> &#x025b6;</xref>; Sasso <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb33"> &#x025b6;</xref>) and recently classified as AroQ<sub>&#x003b3;</sub> (&#x000d6;kvist <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="bb28"> &#x025b6;</xref>), comprises a group of chorismate mutases that exhibit convincing sequence similarity to other AroQ sequences only in the N-terminal moiety (Sasso <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb33"> &#x025b6;</xref>; &#x000d6;kvist <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="bb28"> &#x025b6;</xref>). These enzymes are about twice the size of the classical AroQ<sub>&#x003b1;</sub> domain and feature a cleavable signal peptide responsible for the export of these chorismate mutases from the cytoplasm (Xia <italic>et al.</italic>, 1993<xref ref-type="bibr" rid="bb40"> &#x025b6;</xref>; Calhoun <italic>et al.</italic>, 2001<xref ref-type="bibr" rid="bb5"> &#x025b6;</xref>; Sasso <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb33"> &#x025b6;</xref>). It has been speculated that AroQ<sub>&#x003b3;</sub> enzymes may play some role in the pathogenicity of its producer organism (for a discussion and references, see Sasso <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb33"> &#x025b6;</xref>). Primary structure comparisons suggested that AroQ<sub>&#x003b3;</sub> proteins also have other structural peculiarities (MacBeath <italic>et al.</italic>, 1998<xref ref-type="bibr" rid="bb23"> &#x025b6;</xref>; Sasso <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb33"> &#x025b6;</xref>). In particular, a critical amino-terminal segment carrying a conserved active-site arginine is lacking in AroQ<sub>&#x003b3;</sub> chorismate mutases. Instead, a homologous helical segment is present in the middle of the polypeptide chain, indicating that the structure of the exported AroQ<sub>&#x003b3;</sub> proteins must be topologically distinct from those of the other known AroQ prototypes (Sasso <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb33"> &#x025b6;</xref>). To investigate this issue and to gain insights into the structure&#x02013;function relationship of these enzymes, which have the potential to serve as formidable specific drug targets, we have set out to determine the high-resolution crystal structure of the secreted chorismate mutase from the model pathogen <italic>Mycobacterium tuberculosis</italic> (*MtCM; encoded by open reading frame Rv1885c in strain H37Rv), which represents the first characterized example of an AroQ<sub>&#x003b3;</sub> fold (&#x000d6;kvist <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="bb28"> &#x025b6;</xref>).</p><p>However, crystallization of this enzyme turned out to be non-trivial. While small well ordered crystals could readily be obtained within less than half an hour of setting up the drops, it seemed impossible to obtain (fewer and) larger crystals with better diffraction quality. Common strategies to increase crystal size are to lower the precipitant or protein concentration, thereby moving in the phase diagram from a condition of high supersaturation (where nucleation occurs) to a concentration of lower supersaturation (thus reducing the number of spontaneously formed nuclei, but still staying within the &#x02018;labile&#x02019; zone where nucleation can occur; Mikol &#x00026; Gieg&#x000e9;, 1992<xref ref-type="bibr" rid="bb27"> &#x025b6;</xref>). Another well known factor that can influence nucleation is the temperature, which has an impact both on the phase diagram itself and on equilibration kinetics. As an alternative to temperature variation, the equilibration time might be influenced more predictably by applying a layer of oil on top of the reservoir of a vapour-diffusion setup (Chayen, 1997<xref ref-type="bibr" rid="bb6"> &#x025b6;</xref>). In this way, equilibration is slowed down, warranting controlled entry into the &#x02018;labile&#x02019; nucleation zone.</p><p>All of these protocols work relatively well if the nucleation rate increases gradually upon increasing precipitant or protein concentration. However, if instead there is an abrupt increase in nucleation rate, it can be very difficult to hit the point optimal for both nucleation and crystal growth (if such a point exists at all). In these cases, the application of seeding techniques may be attempted (Stura &#x00026; Wilson, 1992<xref ref-type="bibr" rid="bb38"> &#x025b6;</xref>; Stura, 1999<xref ref-type="bibr" rid="bb37"> &#x025b6;</xref>), which approach the problem from the opposite end by placing crystal nuclei in the form of small seeds into the metastable zone optimal for crystal growth. Finding conditions appropriate for seeding has its own inherent difficulties, however, as the metastable zone can be rather narrow and excursions to either side of the phase diagram will inevitably result in either extensive secondary nucleation or dissolution of the seeds. If only little protein is available, this adds to the challenge. A few years ago, two new approaches to the problem were described (Saridakis <italic>et al.</italic>, 1994<xref ref-type="bibr" rid="bb32"> &#x025b6;</xref>; Saridakis &#x00026; Chayen, 2000<xref ref-type="bibr" rid="bb31"> &#x025b6;</xref>). The first method involves diluting microbatch drops after incubating them for several hours under spontaneous nucleation conditions (Saridakis <italic>et al.</italic>, 1994<xref ref-type="bibr" rid="bb32"> &#x025b6;</xref>), while the second approach relies on transferring cover slips of hanging-drop vapour-diffusion setups from nucleation conditions to the metastable zone (Saridakis &#x00026; Chayen, 2000<xref ref-type="bibr" rid="bb31"> &#x025b6;</xref>). In the present report, we describe the crystal optimization of a protein target that crystallizes very rapidly and show that this problem can be solved by adapting the approach by Saridakis &#x00026; Chayen (2000<xref ref-type="bibr" rid="bb31"> &#x025b6;</xref>) to very short crystallization times.</p></sec><sec sec-type="discussion|interpretation" id="sec2"><label>2.</label><title>Experimental procedures, results and discussion</title><sec id="sec2.1"><label>2.1.</label><title>Crystallization</title><p>Two different protein batches were used for crystallization. In both cases, recombinant *MtCM was prepared from <italic>E. coli</italic> strain KA29 as described in Sasso <italic>et al.</italic> (2005<xref ref-type="bibr" rid="bb33"> &#x025b6;</xref>) and concentrated to 10&#x02013;20&#x02005;mg&#x02005;ml<sup>&#x02212;1</sup>. Immediately prior to crystallization setups, the protein solutions were centrifuged at 10&#x02005;000&#x02005;rev&#x02005;min<sup>&#x02212;1</sup> for 10&#x02005;min at 277&#x02005;K in order to spin down any floating particles and aggregated insoluble protein. Standard initial crystallization tests were then performed by the hanging-drop vapour-diffusion method in 24-well tissue-culture plates (G&#x000f6;teborgs Termometerfabrik, Sweden) using siliconized glass cover slips from Hampton Research (CA, USA).</p><p>For the first crystallization trials, we used a 175-residue version of *MtCM (encoded on plasmid pKTU3-HCT) devoid of the cleavable signal peptide but containing a C-terminal His tag (Sasso <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb33"> &#x025b6;</xref>). The protein sample (12.6&#x02005;mg&#x02005;ml<sup>&#x02212;1</sup>) was dissolved in 20&#x02005;m<italic>M</italic> potassium phosphate buffer pH 7.5. Structure Screen 1 (Molecular Dimensions Ltd, England) gave a few leads, which were optimized, with the best preliminary condition consisting only of 15% PEG 8000 (without buffer). In order to explore different conditions which were not limited by the use of phosphate as buffer, we then switched to protein (18.6&#x02005;mg&#x02005;ml<sup>&#x02212;1</sup>) buffered with 20&#x02005;m<italic>M</italic> Tris&#x02013;HCl pH 8.0. This time, the leaderless untagged 167-residue version of *MtCM encoded by plasmid pKTU3-HT was used (Sasso <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb33"> &#x025b6;</xref>). The first screen at room temperature (293&#x02005;K) gave a hit for condition No. 18 (0.2&#x02005;<italic>M</italic> sodium acetate, cacodylate pH 6.5, 30% PEG 8000). A shower of small, well shaped and strongly birefringent single crystals appeared within 20&#x02005;min of the first crystallization setup (Fig. 1<xref ref-type="fig" rid="fig1"> &#x025b6;</xref><italic>a</italic>). These crystals diffracted to 3&#x02013;4&#x02005;&#x000c5; resolution. Subsequently, an intense effort was invested into optimizing the crystallization conditions and particularly into slowing down crystallization in order to obtain fewer but larger crystals. However, none of the modifications, such as lowering the protein or precipitant concentration, changing the volume ratios and temperature, using additives or layering the reservoirs with various oils <italic>etc</italic>., proved successful: we either still obtained a shower of small crystals within 20&#x02005;min of setting up the drops (using a reservoir concentration of&#x000a0;&#x02265;20% PEG) or we did not obtain any crystals at all. Even seeding did not help. The final breakthrough came when we recalled a publication by Saridakis &#x00026; Chayen (2000<xref ref-type="bibr" rid="bb31"> &#x025b6;</xref>) in which nucleation was initiated at a high precipitant concentration (which is more likely to produce nucleation centres) followed by transferring the drops before crystals became visible macroscopically to reservoirs with a lower precipitant concentration (which is favourable for crystal growth). In our case, crystallization times were extremely short, so the drops needed to be transferred within less than 20&#x02005;min. After initial tests showed dramatic improvements upon implementing this strategy, we adopted a more systematic approach and devised a grid screen in which both the incubation period before transfer and the concentration of the final reservoir solution were varied. The best results were obtained when suspending the drops (1.5&#x02005;&#x000b5;l protein + 1.5&#x02005;&#x000b5;l reservoir solution) over a starting reservoir (1&#x02005;ml) containing 20% PEG 4000 (in addition to 0.2&#x02005;<italic>M</italic> sodium acetate and cacodylate buffer pH 6.5) and then transferring them after 5&#x02013;15&#x02005;min to reservoirs containing only 5&#x02013;15% PEG 4000 (other ingredients constant). In this way, huge crystals (&#x0223c;1&#x02005;mm in the longest dimension) appeared overnight which did not look perfect but diffracted to beyond 1.6&#x02005;&#x000c5; resolution (Fig. 1<xref ref-type="fig" rid="fig1"> &#x025b6;</xref><italic>b</italic>). In general, lower reservoir concentrations and shorter incubation times coincided with fewer (and larger) crystals, with the reservoir concentration having the larger impact (particularly for concentrations of &#x0003c;10% PEG).</p><p>To our knowledge, this is the first time that the technique of Saridakis &#x00026; Chayen (2000<xref ref-type="bibr" rid="bb31"> &#x025b6;</xref>) has been applied to such short crystallization times. Obviously, in time spans as short as a few minutes, equilibration with the reservoir solution cannot occur. Nevertheless, it turned out to be critical for our experiments to initiate crystallization at a PEG concentration of 20% (before transferring the drop to lower concentrations). The reason for this is presumably a rather steep concentration gradient of PEG in the drop immediately after pipetting the reservoir solution onto the protein droplet. In the mixing zone at the interface between protein and precipitant solution, the PEG concentration will be very close to 20%, enabling the formation of crystal nuclei (&#x02018;shock&#x02019; nucleation). The locally high PEG concentration will subsequently decrease by diffusion, establishing conditions favorable for crystal growth, provided that the vapour pressure from the reservoir is sufficiently high to prevent rapid dehydration of the drop, thus avoiding further nucleation.</p></sec><sec id="sec2.2"><label>2.2.</label><title>Preparation of a transition-state analogue inhibitor complex</title><p>In order to localize and investigate the active site of *MtCM, we performed soaks of the unliganded protein crystals in a solution containing an <italic>endo</italic>-oxabicyclic dicarboxylic acid (referred to here as &#x02018;TSA&#x02019;; Bartlett &#x00026; Johnson, 1985<xref ref-type="bibr" rid="bb3"> &#x025b6;</xref>; Bartlett <italic>et al.</italic>, 1988<xref ref-type="bibr" rid="bb4"> &#x025b6;</xref>). This compound is known to be an excellent mimic of the geometry of the transition state of the chorismate mutase reaction and is currently the best inhibitor for a broad range of chorismate mutases (Mandal &#x00026; Hilvert, 2003<xref ref-type="bibr" rid="bb24"> &#x025b6;</xref>), including *MtCM (Sasso <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb33"> &#x025b6;</xref>). Consequently, it has been used as a ligand in many structural studies of chorismate mutases (Chook <italic>et al.</italic>, 1993<xref ref-type="bibr" rid="bb8"> &#x025b6;</xref>, 1994<xref ref-type="bibr" rid="bb7"> &#x025b6;</xref>; Haynes <italic>et al.</italic>, 1994<xref ref-type="bibr" rid="bb14"> &#x025b6;</xref>; Lee, Karplus <italic>et al.</italic>, 1995<xref ref-type="bibr" rid="bb20"> &#x025b6;</xref>; Str&#x000e4;ter <italic>et al.</italic>, 1997<xref ref-type="bibr" rid="bb36"> &#x025b6;</xref>).</p><p>Two different soaking techniques were tested. In order to minimize consumption of the precious compound, we first tried to dissolve a tiny amount of solid TSA directly in a drop containing *MtCM crystals. However, all crystals in the drop dissolved immediately. We then took 0.5&#x02005;&#x000b5;l of this TSA-containing drop and added it to a 1.5&#x02005;&#x000b5;l drop containing more *MtCM crystals. After 20&#x02005;min soaking time, the crystals were cryoprotected by pipetting a drop of mother liquor containing 10% PEG 400 on top of the soak. Thereafter, the crystals were flash-frozen in liquid nitrogen and stored for data collection. Crystal structure analysis (&#x000d6;kvist <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="bb28"> &#x025b6;</xref>) confirmed the presence of TSA in the active site of *MtCM.</p></sec><sec id="sec2.3"><label>2.3.</label><title>X-ray diffraction analysis</title><p>X-ray data were collected and processed as reported by &#x000d6;kvist <italic>et al.</italic> (2006<xref ref-type="bibr" rid="bb28"> &#x025b6;</xref>). *MtCM crystals diffracted to beyond 1.6&#x02005;&#x000c5; resolution (diffraction limit 1.3&#x02005;&#x000c5; resolution; Fig. 2<xref ref-type="fig" rid="fig2"> &#x025b6;</xref> and Table 1<xref ref-type="table" rid="table1"> &#x025b6;</xref>) and belong to the monoclinic space group <italic>P</italic>2<sub>1</sub>, with unit-cell parameters <italic>a</italic> = 42.6, <italic>b</italic>&#x000a0;=&#x000a0;72.6, <italic>c</italic> = 62.0&#x02005;&#x000c5;, &#x003b2; = 104.5&#x000b0; for the free enzyme and <italic>a</italic> = 42.9, <italic>b</italic>&#x000a0;=&#x000a0;72.8, <italic>c</italic> = 61.7&#x02005;&#x000c5;, &#x003b2; = 104.0&#x000b0; for the TSA complex. The Matthews parameter <italic>V</italic><sub>M</sub> is 2.9&#x02005;&#x000c5;<sup>3</sup>&#x02005;Da<sup>&#x02212;1</sup> (Matthews, 1968<xref ref-type="bibr" rid="bb26"> &#x025b6;</xref>; calculated for a unit cell containing two protomers per asymmetric unit), which corresponds to a solvent content of 57%. The dimeric nature of *MtCM is consistent with previous biochemical data (Sasso <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb33"> &#x025b6;</xref>; Prakash <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb29"> &#x025b6;</xref>). Since sequence alignments (Sasso <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb33"> &#x025b6;</xref>) suggested homology to the <italic>E. coli</italic> AroQ<sub>p</sub> domain, phasing was attempted by molecular replacement using the <italic>E. coli</italic> structure (PDB code <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore.do?structureId=1ecm">1ecm</ext-link>; Lee, Karplus <italic>et al.</italic>, 1995<xref ref-type="bibr" rid="bb20"> &#x025b6;</xref>) as a search model. However, even exhaustive trials did not yield a solution to the problem. A probable reason for the failure is the relatively poor overall sequence homology (16% identity, according to <italic>BLASTP</italic> v.2.2.6 from NCBI; Altschul <italic>et al.</italic>, 1997<xref ref-type="bibr" rid="bb1"> &#x025b6;</xref>) between the entire 167-&#x000ad;residue *MtCM polypeptide and the structurally characterized 109-residue <italic>E. coli</italic> AroQ<sub>p</sub> domain, together with significant structural differences of the C-terminal helices (&#x000d6;kvist <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="bb28"> &#x025b6;</xref>).</p><p>We have therefore prepared heavy-atom derivatives (Pb<sup>II</sup> acetate and Tl<sup>III</sup> acetate soaks) and solved the structure by the MAD phasing technique based on the Pb<sup>II</sup> derivative (&#x000d6;kvist <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="bb28"> &#x025b6;</xref>).</p></sec></sec><sec sec-type="conclusions" id="sec3"><label>3.</label><title>Concluding remarks</title><p>While crystallization of the same protein has been reported very recently by another group (Qamra <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="bb30"> &#x025b6;</xref>), our results are distinct since the crystal forms are different (space group <italic>P</italic>2<sub>1</sub> instead of <italic>C</italic>2) and we have significantly higher resolution data (&#x02264;1.6&#x02005;&#x000c5; <italic>versus</italic> 2.1&#x02005;&#x000c5;). Furthermore, we describe the crystallization of free enzyme and a soak with a transition-state analogue, while Qamra and coworkers cocrystallized *MtCM with <sc>l</sc>-tryptophan.</p><p>In addition, this report addresses in detail a general and very challenging crystallization problem and its subsequent solution, which led to the development of an empirical method for crystal optimization for cases with short crystallization times. By applying the optimized protocol, the diffraction limit of the *MtCM crystals could be extended from &#x0223c;3.5 to 1.3&#x02005;&#x000c5;. This technique, which involves the transfer of crystallization drops to lower concentration reservoirs (varying both reservoir concentration and incubation time before transfer), is particularly useful if the protein of interest crystallizes in a narrow window of conditions and only little protein material is available.</p></sec></body><back><ack><p>We would like to thank Rosalino Pulido for TSA synthesis and Elin Grahn for help with data collection. At the synchrotron beamlines ID14-4, ESRF, Grenoble and I711, Max II, Lund, we had excellent support from Raimond Ravelli and Yngve Cerenius, respectively. This work has been supported by grants from the Carl Trygger foundation (research grant No. 02:158 to UK and postdoctoral fellowship of RD) from the Glycoconjugates in Biological Systems program of the Swedish National Foundation for Strategic Research (research position of UK), from Novartis Pharma (to SS) and the ETH Z&#x000fc;rich (PK).</p></ack><ref-list><title>References</title><ref id="bb1"><citation citation-type="journal">Altschul, S. F., Madden, T. L., Sch&#x000e4;ffer, A. A., Zhang, J., Zhang, Z., Miller, W. &#x00026; Lipman, D. J. (1997). <italic>Nucleic Acids Res.</italic><bold>25</bold>, 3389&#x02013;3402.</citation></ref><ref id="bb2"><citation citation-type="journal">Andrews, P. R., Smith, G. D. &#x00026; Young, I. G. (1973). <italic>Biochemistry</italic>, <bold>12</bold>, 3492&#x02013;3498.</citation></ref><ref id="bb3"><citation citation-type="other">Bartlett, P. A. &#x00026; Johnson, C. R. (1985). <italic>J. Am. Chem. Soc.</italic><bold>107</bold>, 7792&#x02013;7793.</citation></ref><ref id="bb4"><citation citation-type="other">Bartlett, P. A., Nakagawa, Y., Johnson, C. R., Reich, S. H. &#x00026; Luis, A. (1988). <italic>J. Org. Chem.</italic><bold>53</bold>, 3195&#x02013;3210.</citation></ref><ref id="bb5"><citation citation-type="other">Calhoun, D. H., Bonner, C. A., Gu, W., Xie, G. &#x00026; Jensen, R. A. (2001). <italic>Genome Biol.</italic><bold>2</bold>, 30.01&#x02013;30.16.</citation></ref><ref id="bb6"><citation citation-type="journal">Chayen, N. E. (1997). <italic>J. Appl. Cryst.</italic><bold>30</bold>, 198&#x02013;202.</citation></ref><ref id="bb7"><citation citation-type="journal">Chook, Y. M., Gray, J. V., Ke, H. &#x00026; Lipscomb, W. N. (1994). <italic>J. Mol. Biol.</italic><bold>240</bold>, 476&#x02013;500.</citation></ref><ref id="bb8"><citation citation-type="journal">Chook, Y. M., Ke, H. &#x00026; Lipscomb, W. N. (1993). <italic>Proc. Natl Acad. Sci. USA</italic>, <bold>90</bold>, 8600&#x02013;8603.</citation></ref><ref id="bb9"><citation citation-type="journal">G&#x000f6;risch, H. (1978). <italic>Biochemistry</italic>, <bold>17</bold>, 3700&#x02013;3705.</citation></ref><ref id="bb10"><citation citation-type="journal">Guimar&#x000e3;es, C. R. W., Repasky, M. P., Chandrasekhar, J., Tirado-Rives, J. &#x00026; Jorgensen, W. L. (2003). <italic>J. Am. Chem. Soc.</italic><bold>125</bold>, 6892&#x02013;6899.</citation></ref><ref id="bb11"><citation citation-type="journal">Guo, H., Cui, Q., Lipscomb, W. N. &#x00026; Karplus, M. (2003). <italic>Angew. Chem. Int. Ed. Engl.</italic><bold>42</bold>, 1508&#x02013;1511.</citation></ref><ref id="bb12"><citation citation-type="other">Gustin, D. J., Mattei, P., Kast, P., Wiest, O., Lee, L., Cleland, W. W. &#x00026; Hilvert, D. (1999). <italic>J. Am. Chem. Soc.</italic><bold>121</bold>, 1756&#x02013;1757.</citation></ref><ref id="bb13"><citation citation-type="other">Haslam, E. (1993). <italic>Shikimic Acid: Metabolism and Metabolites.</italic> New York: John Wiley &#x00026; Sons.</citation></ref><ref id="bb14"><citation citation-type="journal">Haynes, M. R., Stura, E. A., Hilvert, D. &#x00026; Wilson, I. A. (1994). <italic>Science</italic>, <bold>263</bold>, 646&#x02013;652.</citation></ref><ref id="bb15"><citation citation-type="other">Kast, P., Asif-Ullah, M. &#x00026; Hilvert, D. (1996). <italic>Tetrahedron Lett.</italic><bold>37</bold>, 2691&#x02013;2694.</citation></ref><ref id="bb16"><citation citation-type="journal">Kast, P., Asif-Ullah, M., Jiang, N. &#x00026; Hilvert, D. (1996). <italic>Proc. Natl Acad. Sci. USA</italic>, <bold>93</bold>, 5043&#x02013;5048.</citation></ref><ref id="bb17"><citation citation-type="journal">Kast, P., Grisostomi, C., Chen, I. A., Li, S., Krengel, U., Xue, Y. &#x00026; Hilvert, D. (2000). <italic>J. Biol. Chem.</italic><bold>275</bold>, 36832&#x02013;36838.</citation></ref><ref id="bb18"><citation citation-type="journal">Kienh&#x000f6;fer, A., Kast, P. &#x00026; Hilvert, D. (2003). <italic>J. Am. Chem. Soc.</italic><bold>125</bold>, 3206&#x02013;3207.</citation></ref><ref id="bb19"><citation citation-type="journal">Ladner, J. E., Reddy, P., Davis, A., Tordova, M., Howard, A. J. &#x00026; Gilliland, G.&#x000a0;L. (2000). <italic>Acta Cryst.</italic> D<bold>56</bold>, 673&#x02013;683.</citation></ref><ref id="bb20"><citation citation-type="other">Lee, A. Y., Karplus, P. A., Ganem, B. &#x00026; Clardy, J. (1995). <italic>J. Am. Chem. Soc.</italic><bold>117</bold>, 3627&#x02013;3628.</citation></ref><ref id="bb21"><citation citation-type="journal">Lee, A. Y., Stewart, J. D., Clardy, J. &#x00026; Ganem, B. (1995). <italic>Chem. Biol.</italic><bold>2</bold>, 195&#x02013;&#x000ad;203.</citation></ref><ref id="bb22"><citation citation-type="journal">Ma, J., Zheng, X., Schnappauf, G., Braus, G., Karplus, M. &#x00026; Lipscomb, W. N. (1998). <italic>Proc. Natl Acad. Sci. USA</italic>, <bold>95</bold>, 14640&#x02013;14645.</citation></ref><ref id="bb23"><citation citation-type="journal">MacBeath, G., Kast, P. &#x00026; Hilvert, D. (1998). <italic>Biochemistry</italic>, <bold>37</bold>, 10062&#x02013;10073.</citation></ref><ref id="bb24"><citation citation-type="journal">Mandal, A. &#x00026; Hilvert, D. (2003). <italic>J. Am. Chem. Soc.</italic><bold>125</bold>, 5598&#x02013;5599.</citation></ref><ref id="bb25"><citation citation-type="journal">Mattei, P., Kast, P. &#x00026; Hilvert, D. (1999). <italic>Eur. J. Biochem.</italic><bold>261</bold>, 25&#x02013;32.</citation></ref><ref id="bb26"><citation citation-type="journal">Matthews, B. W. (1968). <italic>J. Mol. Biol.</italic><bold>33</bold>, 491&#x02013;497.</citation></ref><ref id="bb27"><citation citation-type="other">Mikol, V. &#x00026; Gieg&#x000e9;, R. (1992). <italic>Crystallization of Nucleic Acids and Proteins</italic>, edited by A. Ducruix &#x00026; R. Gieg&#x000e9;, pp. 219&#x02013;239. Oxford University Press.</citation></ref><ref id="bb28"><citation citation-type="journal">&#x000d6;kvist, M., Dey, R., Sasso, S., Grahn, E., Kast, P. &#x00026; Krengel, U. (2006). <italic>J. Mol. Biol.</italic><bold>357</bold>, 1483&#x02013;1499.</citation></ref><ref id="bb29"><citation citation-type="journal">Prakash, P., Aruna, B., Sardesai, A. A. &#x00026; Hasnain, S. E. (2005). <italic>J. Biol. Chem.</italic><bold>280</bold>, 19641&#x02013;19648.</citation></ref><ref id="bb30"><citation citation-type="other">Qamra, R., Prakash, P., Aruna, B., Hasnain, S. E. &#x00026; Mande, S. C. (2005). <italic>Acta Cryst.</italic> F<bold>61</bold>, 473&#x02013;475.</citation></ref><ref id="bb31"><citation citation-type="journal">Saridakis, E. &#x00026; Chayen, N. E. (2000). <italic>Protein Sci.</italic><bold>9</bold>, 755&#x02013;757.</citation></ref><ref id="bb32"><citation citation-type="journal">Saridakis, E. E. G., Shaw Stewart, P. D., Lloyd, L. F. &#x00026; Blow, D. M. (1994). <italic>Acta Cryst.</italic> D<bold>50</bold>, 293&#x02013;297.</citation></ref><ref id="bb33"><citation citation-type="journal">Sasso, S., Ramakrishnan, C., Gamper, M., Hilvert, D. &#x00026; Kast, P. (2005). <italic>FEBS J.</italic><bold>272</bold>, 375&#x02013;389.</citation></ref><ref id="bb34"><citation citation-type="journal">&#x00160;trajbl, M., Shurki, A., Kato, M. &#x00026; Warshel, A. (2003). <italic>J. Am. Chem. Soc.</italic><bold>125</bold>, 10228&#x02013;10237.</citation></ref><ref id="bb35"><citation citation-type="journal">Str&#x000e4;ter, N., H&#x000e5;kansson, K., Schnappauf, G., Braus, G. &#x00026; Lipscomb, W. N. (1996). <italic>Proc. Natl Acad. Sci. USA</italic>, <bold>93</bold>, 3330&#x02013;3334.</citation></ref><ref id="bb36"><citation citation-type="journal">Str&#x000e4;ter, N., Schnappauf, G., Braus, G. &#x00026; Lipscomb, W. N. (1997). <italic>Structure</italic>, <bold>5</bold>, 1437&#x02013;1452.</citation></ref><ref id="bb37"><citation citation-type="other">Stura, E. A. (1999). <italic>Protein Crystallization: Techniques, Strategies, and Tips</italic>, edited by T. M. Bergfors, pp. 141&#x02013;153. La Jolla, CA, USA: International University Line.</citation></ref><ref id="bb38"><citation citation-type="other">Stura, E. A. &#x00026; Wilson, I. A. (1992). <italic>Crystallization of Nucleic Acids and Proteins</italic>, edited by A. Ducruix &#x00026; R. Gieg&#x000e9;, pp. 99&#x02013;126. Oxford University Press.</citation></ref><ref id="bb39"><citation citation-type="other">Wiest, O. &#x00026; Houk, K. N. (1995). <italic>J. Am. Chem. Soc.</italic><bold>117</bold>, 11628&#x02013;11639.</citation></ref><ref id="bb40"><citation citation-type="journal">Xia, T., Song, J., Zhao, G., Aldrich, H. &#x00026; Jensen, R. A. (1993). <italic>J. Bacteriol.</italic><bold>175</bold>, 4729&#x02013;4737.</citation></ref><ref id="bb41"><citation citation-type="journal">Xu, H., Yang, C., Chen, L., Kataeva, I. A., Tempel, W., Lee, D., Habel, J. E., Nguyen, D., Pflugrath, J. W., Ferrara, J. D., Arendall, W. B. III, Richardson, J.&#x000a0;S., Richardson, D. C., Liu, Z.-J., Newton, M. G., Rose, J. P. &#x00026; Wang, B.-C. (2005). <italic>Acta Cryst.</italic> D<bold>61</bold>, 960&#x02013;966.</citation></ref><ref id="bb43"><citation citation-type="journal">Xue, Y. &#x00026; Lipscomb, W. N. (1995). <italic>Proc. Natl Acad. Sci. USA</italic>, <bold>92</bold>, 10595&#x02013;10598.</citation></ref><ref id="bb42"><citation citation-type="journal">Xue, Y., Lipscomb, W. N., Graf, R., Schnappauf, G. &#x00026; Braus, G. (1994). <italic>Proc. Natl Acad. Sci. USA</italic>, <bold>91</bold>, 10814&#x02013;10818.</citation></ref><ref id="bb44"><citation citation-type="journal">Zhang, X., Zhang, X. &#x00026; Bruice, T. C. (2005). <italic>Biochemistry</italic>, <bold>44</bold>, 10443&#x02013;10448.</citation></ref></ref-list></back><floats-wrap><fig id="fig1" position="float"><label>Figure 1</label><caption><p>(<italic>a</italic>) Photograph of *MtCM crystals obtained straight from initial screens (crystal size &#x0223c;20&#x02005;&#x000b5;m). (<italic>b</italic>) Photograph of *MtCM crystals from optimized crystallization conditions (crystal size &#x0223c;1&#x02005;mm in the longest dimension).</p></caption><graphic xlink:href="f-62-00441-fig1"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Diffraction image from a *MtCM crystal recorded at beamline ID14-4, ESRF, Grenoble. Resolution rings are indicated in (<italic>a</italic>) and a close-up view of the outer rings (<italic>b</italic>) shows that the crystal diffracts to a maximum resolution of 1.3&#x02005;&#x000c5; (see encircled reflection in outer resolution ring).</p></caption><graphic xlink:href="f-62-00441-fig2"/></fig><table-wrap id="table1" position="float"><label>Table 1</label><caption><title>Data-collection statistics</title><p>Values in parentheses are for the highest resolution shells included in the final processing.</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="1" colspan="1" align="left" valign="bottom">Data set</th><th rowspan="1" colspan="1" align="left" valign="bottom">Unliganded *MtCM</th><th rowspan="1" colspan="1" align="left" valign="bottom">TSA complex</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1" align="left" valign="top">Synchrotron beamline</td><td rowspan="1" colspan="1" align="left" valign="top">ESRF, ID14-4</td><td rowspan="1" colspan="1" align="left" valign="top">Max II, I711</td></tr><tr><td rowspan="1" colspan="1" align="left" valign="top">Resolution limit<xref ref-type="table-fn" rid="tfn1">&#x02020;</xref> (&#x000c5;)</td><td rowspan="1" colspan="1" align="left" valign="top">31.01&#x02013;1.55 (1.63&#x02013;1.55)</td><td rowspan="1" colspan="1" align="left" valign="top">38.92&#x02013;1.64 (1.73&#x02013;1.64)</td></tr><tr><td rowspan="1" colspan="1" align="left" valign="top">Completeness (%)</td><td rowspan="1" colspan="1" align="left" valign="top">99.8 (99.8)</td><td rowspan="1" colspan="1" align="left" valign="top">99.5 (96.4)</td></tr><tr><td rowspan="1" colspan="1" align="left" valign="top">Redundancy</td><td rowspan="1" colspan="1" align="left" valign="top">4.1 (4.1)</td><td rowspan="1" colspan="1" align="left" valign="top">4.4 (4.0)</td></tr><tr><td rowspan="1" colspan="1" align="left" valign="top">Mean <italic>I</italic>/&#x003c3;(<italic>I</italic>)</td><td rowspan="1" colspan="1" align="left" valign="top">10.9 (2.5)</td><td rowspan="1" colspan="1" align="left" valign="top">21.4 (7.3)</td></tr><tr><td rowspan="1" colspan="1" align="left" valign="top"><italic>R</italic><sub>merge</sub><xref ref-type="table-fn" rid="tfn2">&#x02021;</xref> (%)</td><td rowspan="1" colspan="1" align="left" valign="top">8.5 (40.0)</td><td rowspan="1" colspan="1" align="left" valign="top">5.0 (15.4)</td></tr><tr><td rowspan="1" colspan="1" align="left" valign="top">PDB code</td><td rowspan="1" colspan="1" align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore.do?structureId=2fp1">2fp1</ext-link></td><td rowspan="1" colspan="1" align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore.do?structureId=2fp2">2fp2</ext-link></td></tr></tbody></table><table-wrap-foot><fn id="tfn1"><label>&#x02020;</label><p>Crystals diffracted to a maximum resolution of &#x0223c;1.3&#x02005;&#x000c5; for both data sets (see Fig. 2<xref ref-type="fig" rid="fig2"> &#x025b6;</xref>); however, final data sets only include data to &#x0223c;1.6&#x02005;&#x000c5; for the following reasons: for unliganded *MtCM, the high-resolution data set was the third of three data sets collected from the same crystal (the preceding two data sets were collected at the MAD peak and edge) and therefore reflections at higher resolution were no longer of acceptable quality and strength. For the TSA complex, data collection was limited to 1.6&#x02005;&#x000c5; for technical reasons.</p></fn><fn id="tfn2"><label>&#x02021;</label><p><italic>R</italic><sub>merge</sub> = <inline-formula><inline-graphic xlink:href="f-62-00441-efi1.jpg" mimetype="image" mime-subtype="gif"/></inline-formula><inline-formula><inline-graphic xlink:href="f-62-00441-efi2.jpg" mimetype="image" mime-subtype="gif"/></inline-formula>.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article> 